Screening and treatment for cardiovascular disease in patients with chronic renal disease

American Journal of Kidney Diseases

Volumn 32, Issue 5 SUPPL. 3, 1998, Pages

  Murphy, Sean W ^a   Foley, Robert N ^a   Parfrey, Patrick S ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Health Sciences Centre St John's   (Canada)

Author keywords

Aspirin; Heart hypertrophy; Kidney failure; Myocardial ishemia; Screening

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY BYPASS GRAFT; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; REVIEW; THROMBOCYTE AGGREGATION; TREATMENT INDICATION;

EID: 0031763512     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9820475     Document Type: Review

References (141)

1. Hennekens CH, Dyken ML, Fuster V: Aspirin as a therapeutic agent in cardiovascular disease. Circulation 96: 2751-2753, 1997
2. US Preventative Services Task Force: Guide to Clinical Preventative Services (ed 2). Baltimore, MD, Williams & Williams, 1996
3. ADA Position Statement: Aspirin therapy in diabetes. Diabetes Care 21:545-546, 1998 (suppl)
4. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-1762, 1998
5. Rabelink TJ, Zwaginga JJ, Kooman HA, Sixma JJ: Thrombosis and hemostasis in renal disease. Kidney Int 46:287-296, 1994
6. Steiner RW, Coggins C, Carvalho AC: Bleeding time in uremia: A useful test to assess clinical bleeding. Am J Hematol 7:107-117, 1979
7. Gordge MP, Neild GH: Platelet function in uremia. Platelets 2:115-123, 1991
8. Mezzano D, Tagle R, Panes O, Perez M, Downey P, Munoz B, Aranda E, Barja P, Thambo S, Gonzalez F, Mezzano S, Pereira J: Hemostatic disorder of uremia: The platelet defect, main determinant of prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 76:312-21, 1996
9. Gordge MP, Faint RW, Rylance PB, Neild GH: Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 60:83-87, 1988
10. Fernandez F, Goudable C, Sie P, Ton-That D, Durand JM: Low hematocrit and prolonged bleeding time in uremic patients: Effect of red cell transfusions. Br J Hematology 59:139-148, 1985
11. Livio M, Marchesi D, Remuzzi G, Gotti E, Mecca G, de Gaetano G: Uremic bleeding: Role of anemia and beneficial effect on red cell transfusions. Lancet 6:1013-1015, 1982
12. Castillo R, Loranzo T, Escolar G, Revert L, Lopez J, Ordinas A: Defective platelet adhesion vessel subendothelium in uremic patients. Blood 68:337-342, 1986
13. Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79: 552-559, 1985
14. Soslau G, Brodsky L, Putatunda B, Parker J, Schwartz AB: Selective reduction of serotonin storage and ATP release in chronic renal failure patient platelets. Am J Hematol 35:171-178, 1990
15. Gralnick HR, McKeown LP, Williams SB, Shafer BC, Pierce L: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 85:806-810, 1988
16. Escolar G, Cases E, Bastida M, Garrido M, Lopez J, Rvert L, Castillo R, Ordinas A: Ureaemic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76:1336-1340, 1990
17. Zwaginga JJ, Ijsseldijk MJW, de Groot PHG, Vos J, de Bos Kuil R, Sixma JJ: Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arterioscler Thromb 11:733-744, 1991
18. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G: Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 86:1768-1771, 1990
19. Noris M, Benigni A, Boccardo P, Aiello S, Caspari F, Todeschini M, Figliuzzi M, Remuzzi G: Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 44:445-450, 1993
20. Lindsay RM, Friesen M, Araonstam A, Andrus F, Clark WF, Linton AL: Improvement in platelet function by increased frequency of hemodialysis. Clin Nephrol 10: 67-70, 1978
21. Lindsay RM, Friesen M, Koens F, Linton AL, Oreopoulos D, De Verber G: Platelet function in patients on long-term peritoneal dialysis. Clin Nephrol 6:335-339, 1976
22. Moia M, Vizzotto L, Cattaneo M, Mannucci PM, Casati S, Ponticcelli C: Improvement in the hemostatic defect in uremia after treatment with recombinant human erythropoietin. Lancet 28:1227-1229, 1987
23. Clyne N, Lins LE, Egberg N: Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis. Clin Nephrol 43:260-267, 1995
24. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F: Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 64:81-90, 1991
25. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G: Plasma parameters of the prothrombotic state in chronic uremia. Nephron 63:273-278, 1993
26. Boisclair MD, Lane, DA, Ireland H, Philippou H, Esnouf P: Proteinase cascade activation in human renal failure. Impaired proteinase regulation in hemodialysis as a mechanism for thombogenesis. Thromb Hemost 69:778A, 1993 (abstr)
27. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchiya S, Marumo F: Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kid Dis 27:848-854, 1996
28. Gris JC, Branger B, Vecina F, Sabadini BA, Fourcade J, Schved JF: Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 46:807-813, 1994
29. Panicucci F, Sagripanti A, Pinori E, Vispi M, Lecchini L, Barsotti G, Giovanetti S: Comprehensive study of hemostasis in chronic uremia. Nephron 33:5-8, 1983
30. Hakim RM, Schafer AI: Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 78:575-580, 1985
31. Scmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ: Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Am J Med 83:411-418, 1987
32. Kobayashi M, Yorioka N, Yamakido M: Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 76:56-61, 1997
33. Grace AA, Barradas MA, Mikhaildis DP, Jeremy JY, Moorhead JF, Swney P, Dandona P: Cyclosporin A enhances platelet aggregation. Kidney Int 32:889-895, 1987
34. Neild GH, Rochi G, Imberti L, Fumagalli F, Brown Z, Remuzzi G, Williams DG: Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 32: 373, 1983 (abstr)
35. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Eng J Med 311:501-505, 1984
36. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of CVD: The Framingham study. JAMA 258:1183-1186, 1987
37. Kellheher CC: Plasma fibrinogen and factor VII as risk factors for CVD. Eur J Epidemiol 8:79-82, 1992 (suppl 1)
38. Moncada S, Vane JR: Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Eng J Med 300:1142-47, 1979
39. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G: Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 79:1788-1797, 1987
40. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet i:414-416, 1986
41. Zuckerman GR, Cornette GL, Clouse RE, Harter HR: Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Int Med 102:588-592, 1985
42. Sreedhara R, Himmelfrab J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45: 1477-1483, 1994
43. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE Jr, Weaver WD: ACC/ AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 28:1328-1428, 1996
44. Cairns J, Théroux P, Armstrong P, Bogaty P, Kells C, Thompson C, Warnica W: Unstable angina - Report from a Canadian expert roundtable. Can J Cardiol 12:1279-1292, 1996
45. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, et al: Unstable Angina: Diagnosis and Management. Clinical Practice Guideline, No. 10 [Agency for Health Care Policy and Research Publications No. 94-0602]. Rockville, MD, US Department of Health and Human Services, 1994
46. Solomon AJ, Gersh BJ: Management of chronic stable angina: Medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery. Ann Int Med 128:216-223, 1998
47. Canadian Cardiovascular Society: Consensus conference on indications for and access to revascularization 1995 (revised June 1997). Can J Cardiol 13:1D-72D, 1997 (suppl D)
48. Weinrauch L, D'Elia JA, Healy RW, Gleason RE, Christlieb R, Leland OS: Asymptomatic coronary artery disease: Angiographic assessment of diabetics evaluated for renal transplantation. Circulation 58:1184-1190, 1978
49. Braun WE, Philips DF, Vidt DG, Novick AC, Nakamoto S, Popowniak KL, Paganini E, Magnusson M, Pohl M, Steinmuller DR, Prouva D, Buszta C: CAD in 100 diabetics with end-stage renal failure. Transplant Proc 16:603-607, 1984
50. Lorber MI, Van Buren CT, Flechner SM, Cameron L, Leatherwood J, Walker WE, Smalling RW, Kahan BD: Pre-transplant coronary arteriography for diabetic renal transplant recipients. Transplant Proc 19:1539-1541, 1987
51. Wizemann V: CAD in dialysis patients. Nephron 74:642-651, 1996
52. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30:8192-8240, 1997 (suppl 3)
53. Barrett BJ: Contrast nephrotoxicity. J Am Soc Nephrol 5:125-137, 1994
54. Barrett BJ, Carlisle EJ: Metaanalysis of the relative nephrotoxicity of high and low-osmolality iodinated contrast media. Radiology 188:171-178, 1993
55. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416-1420, 1994
56. Marshall WG, Rossi NP, Meng RL, Wedige-Stecher T: Coronary artery bypass grafting in dialysis patients. Ann Thorac Surg 42:S12-S15, 1986 (suppl 6)
57. Rostand SG, Kirk KA, Rutsky EA, Pacifico AD: Results of coronary artery bypass grafting in end-stage renal disease. Am J Kidney Dis 12:266-270, 1988
58. Opsahl JA, Husebye DG, Helseth HK, Collins AJ: Coronary artery bypass surgery in patients on maintenance hemodialysis: long term survival. Am J Kidney Dis 12:271-274, 1988
59. Deutsch E, Berstein RC, Addonizio VP, Kassmaul WG: Coronary artery bypass surgery in patients on chronic hemodialysis: A case-control study. Ann Intern Med 110:369-372, 1989
60. Blakeman BP, Sullivan HJ, Foy BK, Sobotka PA, Pifarre R: Internal mammary artery revascularization in the patient on long term hemodialysis. Ann Thorac Surg 50:776-778, 1990
61. Batiuk TD, Kurtz SB, Oh JK, Orszulak TA: Coronary artery bypass operation in dialysis patients. Mayo Clin Proc 66:45-53, 1991
62. Ko W, Krieger KH, Isom OW: Cardiopulmonary bypass procedures in dialysis patients. Ann Thorac Surg 55:677-684, 1993
63. Owen CH, Cummings RG, Sell TL, Schwab SJ, Jones RH, Glower DD: Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg 58: 1729-1733, 1994
64. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA: A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 25: 281-290, 1995
65. Koyanagi T, Nishida H, Kitamura M, Endo M, Koyanagi H, Kawaguchi M, Magosaki N, Sumiyoshi T, Hosoda S: Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann Thorac Surg 61:1793-1796, 1996
66. Samuels LE, Sharma S, Morris RJ, Kuretu ML, Grunewald KE, Strong MD 3rd, Brockman SK: Coronary artery bypass grafting in patients with chronic renal failure: A reappraisal. J Card Surg 11:128-133, 1996
67. Jahangiri M, Wright J, Edmondson S, Magee P: Coronary artery bypass graft surgery in dialysis patients. Heart 78:343-345, 1997
68. CASS principal investigators and their associates: Coronary artery surgery study (CASS): A randomized trial of coronary artery bypass surgery: Survival data. Circulation 68:939-950, 1983
69. Venlatesan J, Henrich WL: Cardiac disease in chronic uremia: management. Adv Renal Replace Ther 4:249-266, 1997
70. US Renal Data System: USRDS 1997 Annual Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Disease, 1997
71. Manske CL, Wang Y, Rector T, Wilson RF, White CW: Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet 340:998-1002, 1992
72. Zanardo G, Michielon P, Paccagnella A, Rosi P, Calo M, Salandin V, Da Ros A, Michieletto F, Simini G: Acute renal failure in the patient undergoing cardiac operation. J Thorac Cardiovasc Surg 107:1489-1495, 1993
73. Rao V, Weisel RD, Buth KJ, Cohen G, Borger MA, Shiono N, Bhatnagar G, Fremes SE, Goldman BS, Christakis GT: Coronary artery bypass grafting in patients with non-dialysis dependent renal insufficiency. Circulation 96:11-38-11-45, 1997 (suppl 2)
74. Williams ME: Nephrology forum: management of the diabetic transplant recipient. Kidney Int 48:1660-1674, 1995
75. Braun WE: Nephrology forum: Long-term complications of renal transplantation. Kidney Int 37:1363-1378, 1990
76. De Meyer M, Wyns W, Dion R, Khoury G, Pirson Y, van Ypersele De Stirihou C: Myocardial revascularization in patients on renal replacement therapy. Clin Nephrol 36:147-151, 1991
77. Christiansen S, Splittgerber FH, Marggraf G, Claus M, Philipp T, Zerowski HR, Reideemeister JC: Results of cardiac operations in five kidney transplant patients. Thorac Cardiovasc Surg 45:75-77, 1997
78. Hueb WA, Oliveira SA, Bittencourt D, Bellotti G, Jatene AD, Pileggi F: Coronary artery bypass surgery for patients with renal transplantation. Cardiology 73:151-155, 1986
79. Defraigne JO, Meurisse M, Limet R: Valvular and coronary surgery in renal transplant patients. J Cardiovasc Surg 31:581-583, 1990
80. Bolman RM, Anderson RW, Molina JE, Schwartz JS, Levine B, Simmons RL, Najarian JS: Cardiac operations in patients with functioning renal allografts. J Thorac Cardiovasc Surg 88:537-543, 1984
81. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzler GO: Short and long term outcomes of percutaneous transluminal angioplasty in chronic dialysis patients. Am Heart J 119:484-489, 1990
82. Reusser LM, Osborn LA, White HJ, Sexson R, Crawford MH: Increased morbidity after coronary angioplasty in patients on chronic hemodialysis. Am J Cardiol 73:965-967, 1994
83. Ahmed WH, Shubrooks SJ, Gibson M, Bairn DS, Bittl JA: Complications and long term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. Am Heart J 128:252-255, 1994
84. Schoebel FC, Gradaus F, Ivens K, Heering P, Jax TW, Grabensee B, Strauer BE, Leschke M: Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: A case-control study using quantitative coronary angiography. Heart 78:337-342, 1997
85. Toriyama T, Yokoya M, Matsuo, Kawahara H: Effects of intervention with new devices on calcified coronary artery in hemodialysis (HD) patients. J Am Soc Nephrol 8:255A, 1997 (abstr)
86. Kishore KK, Silver M, Vatsavai SR, Whitlow PL, Nally JV: Coronary stenting in ESRD patients. J Am Soc Nephrol 8:140A, 1997 (abstr)
87. Landau C, Lange RA, Hillis LD: Percutaneous transluminal coronary angioplasty. N Eng J Med 330:981-993, 1994
88. Collins A, Ma J, Herzog C: A national comparison of PTCA vs. CAB in chronic dialysis patients. J Am Soc Nephrol 7:1442, 1996 (abstr)
89. Levy D, Salomon M, D'Agostino R, Belanger A, Kannel W: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90:1786-1793, 1994
90. Yuranev AP, Dyakonaova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, Wallrabe D, Tsifkova R, Romanovska L, Niderle P, Tsiskarishvili D, Davarashvili T, Gelovani K, Kochachidze T, Balash A: Management of essential hypertension in patients with different degrees of LVH: Mulitcenter trial. Am J Hypertens 3:512-517, 1990
91. Schmieder RE, Martus P, Klingbeil A: Reversal of LVH in essential hypertension: A meta-analysis of randomized, double blind studies. JAMA 275:1507-1513, 1996
92. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ: The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Circulation 95:2007-2014, 1997
93. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
94. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446, 1997
95. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11: 1277-1285, 1996
96. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy: Prevalence, associations and prognosis. Kidney Int 47:186-192, 1995
97. Silberberg JS, Barre P, Prichard S, Sniderman AD: LVH: An independent predictor of survival in end-stage renal failure. Kidney Int 36:286-290, 1989
98. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent LVH in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
99. London DM, Fabiani F: Left ventricular dysfunction on end-stage renal disease. Echocardiographic insights, in Parfrey PS, Harnett JD (eds): Cardiac Dysfunction in Chronic Uremia. Boston, MA, Kluwer Academic, 1992, pp 117-137
100. Greaves SC, Gamble GD, Collins JF, Whalley JA, Sharpe DN: Determinants of LVH and systolic dysfunction in chronic renal failure. Am J Kidney Dis 24:768-776, 1994
101. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
102. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS: Risk factors for the development of LVH in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 4:1486-1490, 1994
103. Cannella G, Paoletti E, Delfmeo R, Peloso G, Molinari S, Traverso GB: Regression of LVH in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44:881-886, 1993
104. Dydadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG: ACE inhibitors captopril and enalapril induce regression of LVH in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12:945-951, 1997
105. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
106. Cruikshank JM, Lewis J, Moore V, Dodd C: Reversibility of LVH by differing types of antihypertensive therapy. J Hum Hypertens 6:85-90, 1992
107. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari: Prolonged therapy with ACE inhibitors induces a regression of LVH of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 5:659-664, 1997
108. Sniderman AD, Silberberg JS, Prichard S, Barre PE: Anemia and left ventricular function in end stage renal disease, in Parfrey PS, Harnett JD (eds): Cardiac dysfunction in chronic uremia. Boston MA, Kluwer Academic, 1992, pp 161-171
109. Foley RN, Parfrey PS, Harnett JD, Kent GM, Mur-ray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
110. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
111. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878-882, 1989
112. Low I, Grutzmacher P, Bergmann M, Schoeppe W: Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoetin. Clin Nephrol 31:26-30, 1989
113. Silberberg J, Racine N, Barre PE, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6:1-4, 1990
114. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuna J: Regression of LVH after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 35:280-287, 1991
115. Braun W, Marwick TH: Coronary artery disease in renal transplant recipients. Cleve Clinic J Med 61:370-385, 1994
116. Murphy SW, Parfrey PS: Screening for cardiovascular disease in dialysis patients. Curr Opin Nephrol Hyperten 5:532-540, 1996
117. Eagle KA, Brundage BH, Chaitman BR, Ewy GA, Fleisher LA, Hertzer NL: Guidelines for perioperative cardiovascular evaluation for non-cardiac surgery. Report of the ACC/AHA task force on practice guidelines (committee on perioperative cardiovascular evaluation for non-cardiac surgery). J Am Coll Cardiol 27:910-948, 1996
118. ACP clinical guideline: Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major non-cardiac surgery. Ann Int Med 127:309-312, 1997
119. Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA, Lundin PA, Murphy KJ: The evaluation of renal transplant candidates: clinical practice guidelines. J Am Soc Nephrol 6:1-34, 1995
120. de Lemos JA, Hillis LD: Diagnosis and management of CAD in patients with end-stage renal disease. J Am Soc Nephrol 7:2044-2054, 1996
121. Philipson JD, Carpenter BJ, Itzkoff J, Hakala TR, Rosenthal JT, Taylor RJ, Puschett JB: Evaluation of cardiovascular risk for renal transplantation in diabetic patients. Am J Med 81:630-634, 1986
122. Braun WE, Phillips DF, Vidt DG: CAD in 100 diabetics with end stage renal failure. Transplant Proc 16:603-607, 1984
123. Weinrauch L, D'Elia JA, Healy RW, Gleason RE, Christlieb AR, Leland OS: Asymptomatic CAD: angiographic assessment of diabetics evaluated for renal transplantation. Circulation 58:1184-1190, 1978
124. Coley CM, Eagle KA: Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Curr Probl Cardiol 5:290-382, 1996
125. Morrow CE, Schwartz JS, Sutherland DE, Simmons RL, Ferguson RM, Kjellstrand CM, Najarian JS: Predictive value of thallium stress testing for coronary and cardiovascular events in uremic diabetic patients before renal transplantation. Am J Med 81:63-634, 1983
126. Dahan M, Lagallicier B, Himbert D, Faraggi M, Aubry N, Siohan N, Siohan P, Viron B, Gourgon R, Mignon F: Diagnostic value of myocardial thallium stress scintigraphy in the selection of CAD in patients undergoing chronic hemodialysis. Arch Mal Coeur 88:1121-1123, 1995
127. Boudreau RJ, Strony JT, du Cret RP, Kuni CC, Wang Y, Wilson RF, Schwartz JS, Castaneda-Zuniga WR: Perfusion thallium imaging of type I diabetes patients with end-stage renal disease: Comparison of oral and intravenous dipyridamole administration. Radiology 175:103-105, 1990
128. Marwick TH, Steinmuller DR, Underwood DA, Hobbs RT, Raymundo TG, Swift C, Braun WE: Ineffectiveness of dipyridmole SPECT thallium imaging as a screening technique for CAD in patients with end stage renal failure. Transplantation 49:100-103, 1990
129. Derfler K, Kletter K, Balacke P, Heinz G, Dudczak R: Predictive value of thallium 201 dipyridamole myocardial stress scinitigraphy in chronic hemodialysis patients and transplant recipients. Clin Nephrol 36:192-201, 1991
130. Marcen R, Lamas S, Orofino L, Quereda C, Barcia F, Castro JM, Alonso-de-Caso P, Ortuno J: Dipyridamole thallium 201 perfusion imaging for the study of ischemic heart disease in hemodialysis patients. Int J Artif Organs 12:773-777, 1989
131. Camp AD, Garvin PJ, Hoff J, Marsh J, Byers SL, Chaitman BR: Prognostic value of intravenous dipyridiamole thallium imaging in patients with diabetes mellitus considered for renal transplantation. Am J Cardiol 65:1459-1463, 1990
132. Brown KA, Rimmer J, Haisch C: Non-invasive risk stratification of diabetic and non-diabetic uremic renal allograft candidates using dipyridamole thallium 201 imaging and radionucleotide ventriculography. Am J Cardiol 64:1017-1021, 1989
133. Resis G, Marcovitz PA, Leichtman AB, Merion RM, Fay WP, Werns SW, Armstrong WF: Usefulness of dobutamine stress echocardiography in detecting CAD in end-stage renal disease. Am J Cardiol 75:707-710, 1995
134. Albanese J, Nally J, Marwick T, D'Hondt AM, Wijins W, Vanpersele C: Dobutamine echocardiography is effective in the non-invasive detection of prognostically important CAD in patients with end-stage renal disease. J Am Soc Nephrol 5:322, 1994 (abstr)
135. Bates JR, Sawada SG, Segar DS, Spaedy AJ, Petrovic O, Fineberg NS, Fiegenbaum, Ryna T: Evaluation using dobutamine stress echocardiography in patients with insulin dependent diabetes mellitus before kidney and/or pancreas transplant. Am J Cardiol 77:175-179, 1996
136. Cohn PF: Detection and prognosis of asymptomatic patients with silent myocardial ischemia. Am J Cardiol 61:4B-6B, 1988 (suppl3)
137. Hickman JR, Uhl JS, Cook RL, Engel PH, Hoprik A: A natural history study of asymptomatic CAD. Am J Cardiol 45:422, 1980 (abstr)
138. Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G: The reliability and validity of echocardiographic measurement of left ventricular mass in hemodialysis patients. Nephron 65:212-214, 1993
139. BeSakab A, Berton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339;584-590, 1998
140. Adamson JW, Eschbach JW: Erythropoietin for endstage renal disease. N Engl J Med 339;625-627, 1998
141. Dahan M, Viron BM, Faraggi M, Himbert DL, Legallicier BJJ, Kolta AM, Pessione F, Le Guludec D, Gourgon R, Mignon FE: Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thalbium imaging in hemodialysis patients. Kidney Int 54:255-262, 1998